NasdaqCM - Nasdaq Real Time Price USD

ZyVersa Therapeutics, Inc. (ZVSA)

Compare
0.6325
+0.0452
+(7.60%)
As of 10:14:58 AM EDT. Market Open.
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
9,136.8340
9,136.8340
14,420.7740
13,013.0640
7,704.3760
Operating Income
-9,136.8340
-9,136.8340
-14,420.7740
-13,013.0640
-7,704.3760
Net Non Operating Interest Income Expense
-269.8560
-269.8560
0.4570
-427.5420
-821.3660
Other Income Expense
-408.4000
--
-93,333.4590
-607.0010
441.5810
Pretax Income
-9,406.6900
-9,406.6900
-107,753.7760
-14,047.6070
-8,084.1610
Tax Provision
6.7450
6.7450
-9,455.8300
--
--
Net Income Common Stockholders
-9,413.4350
-9,413.4350
-106,246.1550
-24,063.4440
-8,084.1610
Diluted NI Available to Com Stockholders
-9,413.4350
-9,413.4350
-106,246.1550
-24,063.4440
-8,084.1610
Basic EPS
-8.48
--
-1.09k
-346.10
-139.88
Diluted EPS
-8.48
--
-1.09k
-346.10
-139.88
Basic Average Shares
1,110.0330
--
97.5000
69.2050
57.7920
Diluted Average Shares
1,110.0330
--
97.5000
69.2050
57.7920
Total Operating Income as Reported
-9,136.8340
-9,136.8340
-107,754.2330
-13,013.0640
-7,704.3760
Total Expenses
9,136.8340
9,136.8340
14,420.7740
13,013.0640
7,704.3760
Net Income from Continuing & Discontinued Operation
-9,413.4350
-9,413.4350
-98,297.9460
-14,047.6070
-8,084.1610
Normalized Income
-9,413.4350
-9,413.4350
-13,154.8758
-13,440.6060
-8,525.7420
Interest Income
--
--
0.4570
--
--
Interest Expense
582.5370
--
--
427.5420
821.3660
Net Interest Income
-269.8560
-269.8560
0.4570
-427.5420
-821.3660
EBIT
-9,136.8340
-9,136.8340
-14,420.7740
-13,620.0650
-7,262.7950
EBITDA
-9,129.9010
-9,129.9010
-14,410.3740
-13,610.1970
-7,252.3950
Reconciled Depreciation
6.9330
6.9330
10.4000
9.8680
10.4000
Net Income from Continuing Operation Net Minority Interest
-9,413.4350
-9,413.4350
-98,297.9460
-14,047.6070
-8,084.1610
Total Unusual Items Excluding Goodwill
--
--
-93,333.4590
-607.0010
441.5810
Total Unusual Items
--
--
-93,333.4590
-607.0010
441.5810
Normalized EBITDA
-9,129.9010
-9,129.9010
78,923.0850
-13,003.1960
-7,693.9760
Tax Rate for Calcs
0.0002
0.0002
0.0001
--
--
Tax Effect of Unusual Items
--
--
-8,190.3888
--
--
12/31/2021 - 2/11/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.